Nirsevimab to reduce infant morbidity from respiratory syncytial virus

Bahaa Abu-Raya1, Joanne M Langley2, Pascal Lavoie2

  • 1Canadian Center for Vaccinology (Abu-Raya, Langley), Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority; Departments of Pediatrics (Abu-Raya, Langley), of Microbiology and Immunology (Abu-Raya), and of Community Health and Epidemiology (Langley), Dalhousie University, Halifax, NS; Department of Pediatrics (Lavoie), University of British Columbia, Vancouver, BC. Bahaa.AbuRaya@dal.ca.

Summary

No abstract available in PubMed .

Related Concept Videos